肥胖症 中国就医指南

Obesity is a chronic, relapsing, multifactorial disease characterized by excessive accumulation of body fat that impairs health and increases the risk of comorbidities. Defined clinically as a body mass index (BMI) ≥30 kg/m² in adults, obesity is not merely a cosmetic concern but a systemic endocrine disorder involving dysregulation of appetite control, energy homeostasis, adipokine secretion, insulin sensitivity, and neurohormonal signaling—particularly within the hypothalamus–pituitary–adipose axis. Pathogenesis involves complex interactions among genetic susceptibility (e.g., variants in FTO, MC4R), epigenetic modifications, gut microbiota dysbiosis, environmental drivers (ultra-processed food abundance, sedentary behavior, sleep deprivation, endocrine-disrupting chemicals), and psychosocial factors (chronic stress, depression, food addiction). Globally, obesity prevalence has nearly tripled since 1975: WHO estimates over 650 million adults (13% of the world’s adult population) were obese in 2022, with China reporting a national adult obesity rate of ~16.4% (2023 China Chronic Disease and Risk Factor Surveillance), rising sharply among urban youth and aging populations. Key modifiable risk factors include low physical activity (<150 min/week moderate-intensity exercise), high intake of added sugars and saturated fats, prolonged screen time, shift work, and socioeconomic disadvantage; non-modifiable risks include family history, certain genetic syndromes (e.g., Prader–Willi), and early-life factors (maternal obesity, rapid infant weight gain). Obesity profoundly diminishes quality of life—contributing to mobility limitations, chronic pain (especially knee osteoarthritis), obstructive sleep apnea, social stigma, workplace discrimination, anxiety and depression, reduced sexual function, and diminished self-efficacy. It is a leading preventable cause of type 2 diabetes, cardiovascular disease, non-alcoholic fatty liver disease (NAFLD), certain cancers (endometrial, colorectal, postmenopausal breast), and all-cause mortality. Endocrinologists play a central role in diagnosing obesity as a disease—not a lifestyle failure—and managing it through comprehensive, person-centered care that integrates behavioral therapy, pharmacotherapy (e.g., GLP-1 receptor agonists like semaglutide), metabolic surgery evaluation, and longitudinal monitoring of cardiometabolic biomarkers. Early intervention significantly improves long-term outcomes, underscoring the importance of routine BMI screening, waist circumference measurement, and personalized risk stratification in primary and specialty endocrine practice.

# 肥胖症（内分泌科）治疗方案与费用明细（人民币/RMB）

一、非手术保守治疗

适用人群：BMI 24–39.9 kg/m²，无严重心肺并发症，伴胰岛素抵抗或代谢综合征者。

• •生活方式干预（含营养+运动处方+行为疗法）：3个月周期，三甲医院内分泌科门诊管理

- 必查项目（空腹血糖、HbA1c、血脂四项、肝肾功、甲状腺功能、腹部超声）：680–920元

• •药物治疗（需内分泌科评估后处方）

二、手术/介入治疗

适用人群：BMI≥37.5 kg/m²，或≥32.5 kg/m²伴2型糖尿病/OSAHS等并发症，经规范内科治疗失败者。

• •腹腔镜袖状胃切除术（LSG）（主流术式）

- 手术+麻醉+住院（7–10天）：48,000–65,000元（含三甲医院医保报销后自付部分）

三、复杂/并发症导向治疗

适用人群：重度肥胖（BMI≥45）、合并难治性T2DM、重度OSAHS、NASH肝硬化前期者

• •多学科联合管理（内分泌+减重外科+呼吸科+肝病科）：首年综合管理费 12,000–20,000元（含动态血糖监测、睡眠呼吸监测、肝纤维化扫描等专项评估）

方案快速选择指南

• •预算≤5,000元/年：首选生活方式干预+奥利司他（基础代谢管理）
• •预算1.5–3万元+伴糖尿病：GLP-1药物联合强化随访（医保覆盖部分适应症）
• •预算≥5万元+BMI≥35伴并发症：评估LSG手术（长期成本效益最优）